Evidence map›Paper›PMID 33310870›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2021

Harnessing the Versatility of Invariant NKT Cells in a Stepwise Approach to Sepsis Immunotherapy.

Joshua Choi, Tina S Mele, Steven A Porcelli, Paul B Savage, S M Mansour Haeryfar

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Joshua ChoiDepartment of Microbiology and Immunology, Western University, London, Ontario N6A 5C1, Canada.ORCID 0000-0003-0387-6852
Tina S MeleDivision of General Surgery, Department of Surgery, Western University, London, Ontario N6A 5A5, Canada.ORCID 0000-0002-6617-9790
Steven A PorcelliDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, New York City, NY 10461.
Paul B SavageDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602.
S M Mansour HaeryfarDepartment of Microbiology and Immunology, Western University, London, Ontario N6A 5C1, Canada; mansour.haeryfar@schulich.uwo.ca.ORCID 0000-0002-1125-8176
Western University · CAAlbert Einstein College of Medicine · USBrigham Young University · US

Funding

Precision Targeting of CD1-Restricted iNKT Cells for Cancer ImmunotherapyR01AI045889 · NIAID · YESHIVA UNIVERSITY · PI Steven A Porcelli · 1999 to 2026
$9.3M
CIHR PJT-156295NIAID NIH HHS R01 AI045889
6 · The paper itself

Abstract

Sepsis results from a heavy-handed response to infection that may culminate in organ failure and death. Many patients who survive acute sepsis become immunosuppressed and succumb to opportunistic infections. Therefore, to be successful, sepsis immunotherapies must target both the initial and the protracted phase of the syndrome to relieve early immunopathology and late immunosuppression, respectively. Invariant NKT (

Indexed as

AnimalsCecumCells, CulturedClonal AnergyDisease Models, AnimalGalactosylceramidesHumansImmunotherapyLymphocyte ActivationMiceMice, Inbred BALB CMice, Inbred C57BLNatural Killer T-CellsSepsisTh2 Cellsalpha-galactosylceramideGalactosylceramides

Identifiers

PMID33310870
PMCPMC7785635
OpenAlexW3112208308

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.